Affinity Asset Advisors LLC Purchases Shares of 586,904 Enliven Therapeutics, Inc. $ELVN

Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 586,904 shares of the company’s stock, valued at approximately $23,007,000. Enliven Therapeutics accounts for 1.2% of Affinity Asset Advisors LLC’s holdings, making the stock its 27th biggest position.

Other large investors have also recently made changes to their positions in the company. Tudor Investment Corp ET AL purchased a new stake in Enliven Therapeutics in the third quarter worth $334,000. Candriam S.C.A. increased its position in Enliven Therapeutics by 31.1% during the 1st quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock valued at $23,288,000 after purchasing an additional 141,060 shares during the period. Capricorn Fund Managers Ltd purchased a new position in Enliven Therapeutics during the 1st quarter valued at $14,480,000. Seven Fleet Capital Management LP bought a new position in Enliven Therapeutics in the 4th quarter worth $180,000. Finally, Jennison Associates LLC purchased a new stake in shares of Enliven Therapeutics in the 1st quarter worth about $12,120,000. 95.08% of the stock is currently owned by institutional investors.

Insider Transactions at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 26,018 shares of company stock worth $1,113,888. 3.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price objective for the company. Stifel Nicolaus lifted their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, HC Wainwright increased their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Enliven Therapeutics Trading Up 0.3%

Enliven Therapeutics stock opened at $52.95 on Friday. The business’s fifty day simple moving average is $45.49 and its two-hundred day simple moving average is $37.27. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $54.88. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -31.71 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.